ClinicalTrials.gg
Not yet recruitingNCT06885567Updated Mar 20, 2025

A Phase 2 Study to Evaluate the Safety and Efficacy of BEY2153 in Patients with Early Alzheimer's Disease

A Phase 2 interventional study of BEY2153 and Placebo in Alzheimer Disease and Alzheimer' Disease, sponsored by BeyondBio Inc.. Not yet recruiting at 3 sites in Korea, Republic of. Open to participants aged 55 Years to 85 Years. Per ClinicalTrials.gov, last updated 2025-03-20.

Sponsored by BeyondBio Inc. · Phase 2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
90
Allocation
Randomized
Ages
55 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 174 studies in Alzheimer Disease with a site in Korea, Republic of — 34 open to participants now, 46 under way, 16 of them phase 3. Alzheimer Disease · Korea, Republic of.

Planned enrollment
104th of 157
90 · median 206
Started
2025
with 16 others
Phase 2
27 of 174
5 open now
Primary completion
2028-07
later than 29 of 45 live
Registered
154th of 174
by date

Among the 174 studies in Alzheimer Disease with a site in Korea, Republic of, this one is the 104th largest by planned enrollment of the 157 interventional ones that give a count, is one of 17 that started in 2025, is one of 27 in phase 2, reaches primary completion later than 29 of the 45 other live ones, and was the 154th registered.

Alzheimer Disease

3,972 studies on the registry are indexed under Alzheimer Disease; 930 are open to participants now.

Browse Alzheimer Disease studies →

Open to participants now

34 of the 174 studies in Alzheimer Disease with a site in Korea, Republic of are open now. Recruiting first, the newest first:

29 more — sign in →

All 34 open studies →

A study can be open while its sites in Korea, Republic of have not opened yet or have stopped. Only those recruiting at a site in Korea, Republic of →

Who these studies take

Of the 645 Alzheimer Disease studies recruiting now, 282 (44%) set no upper age limit and 57 (9%) stop at 75 or younger; 34 take children under 18; 288 take healthy volunteers.

This study: 55 Years to 85 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 174 studies in Alzheimer Disease with a site in Korea, Republic of, or all of them as a file.
02

Study summary

The purpose of this study is to investigate the safety and efficacy of BEY2153 in patients with early Alzheimer's Disease. Subjects who meet the inclusion and exclusion criteria will be randomized 1:1:1 to one of three treatment arms for 26 weeks administration. The extension study for additional 26 weeks will be conducted open-label with one treatment arm. Subjects will take BEY2153 orally once a day during the study.

03

Conditions studied

  • Alzheimer Disease
  • Alzheimer' Disease
04

Who can participate

Ages eligible
55 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria:

  • Male and female adults at the age of ≥ 55 to ≤ 85 at the time of
  • Patients diagnosed according to the NIA-AA 2024 Criteria for Diagnosis with Mild Cognitive Impairment (MCI) or diagnosed with mild Alzheimer's disease
  • CDR-GS 0.5-1.0 at Screening
  • ≥ 20 at Screening
  • Amyloid-positive at amyloid PET scan
  • Patients who are capable of understanding information provided and can voluntarily sign written informed consent form

Exclusion Criteria:

  • Subjects diagnosed with cognitive impairment due to causes other than substrate causes such as brain lesions, psychiatric disorders, or Alzheimer's disease (e.g., stroke, Parkinson's disease, Lewy body disease, vascular dementia)
  • Subjects with any of the following cardiovascular diseases at Screening

    * Cerebrovascular disease within the past 6 months (cerebral infarction, cerebral hemorrhage, , etc.)

    • Myocardial infarction or unstable angina pectoris within the past 6 months
    • (NYHA) Class II congestive heart failure
    • ≥450 msec or (ECG) abnormalities
  • Patients with malignant tumors
  • Patients with medical conditions that can affect cognitive decline such as hypothyroidism, vitamin B12 or folate deficiency, niacin deficiency, etc.
  • Patients with a history of alcohol related disorders within the past 6 months
  • Patients with a positive antibody test result at Screening
  • Patients with a positive HBs antigen or antibody test at Screening
  • Patients with active bacterial infections who have received antibiotics within 7 days prior to Screening.
  • Patients with a history of to any of the components of product
  • Patients who have been hospitalized or treated for suicidal behavior within 5 years prior to Screening or whose C-SSRS results at Screening indicate serious suicidal ideation or behavior
  • Patients who have received treatment for Alzheimer's disease (e.g., Lecanemab) within 6 months prior to Screening
  • Patients expected to require the administration of a long-acting benzodiazepine (BDZ) for the treatment of sleep disorders at Screening
  • Any of the following laboratory test values at Screening:

    • Serum Creatinine >1.5× or (MDRD) \<40 mL/min/1.73 m2
    • Any of the following: , ALT >3×ULN, or Total >2xULN
  • Women who test positive for pregnancy at Screening, or women and men of who are planning to become pregnant, or who do not agree to use adequate * during the study and for 4 weeks after the end of study drug administration

    *Adequate contraception: complete abstinence, hormonal contraceptives with no known drug interactions [Levonorgestrel intrauterine system (IUS) (Mirena), Medroxyprogesterone], surgical sterilization (including vasectomy, bilateral salpingectomy and ligation). However, intermittent abstinence (e.g., using ovulation timing, symptothermal method, or post-ovulation) or external ejaculation are not considered adequate contraception.

  • Pregnant or lactating women or women who are tested positive for pregnancy at Screening
  • Patients treated with other IP within 4 weeks prior to screening
  • Patients who are considered ineligible for study participation for other reasons based on the judgment of the investigator

[Extension Study]

Inclusion Criteria:

  • Patients who completed the 26-week visit in the Main Study
  • Patients who provided written consent to participate in the Extension Study

Exclusion Criteria:

  • Subjects who have dropped out of the Main Study
  • Patients who, in the investigator's judgement, are not suitable for participation in Extension Study
  • Any of the following laboratory test values at Baseline:

    • Serum Creatinine >1.5×ULN or eGFR (MDRD) \<40 mL/min/1.73 m2
    • Any of the following: AST, ALT >3×ULN, or Total bilirubin >2xULN
Terms in these criteria, in plain language(17)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
90 participants (estimated)

Study arms

  • Experimental
    BEY2153 dose 1

    Participants administer 26 weeks

    Drug: BEY2153

  • Experimental
    BEY2153 dose 2

    Participants administer 26 weeks

    Drug: BEY2153

  • Placebo comparator
    Placebo

    Participants administer 26 weeks

    Drug: Placebo

Interventions

  • DrugBEY2153

    Participants administer once daily, PO, 26 weeks

  • DrugPlacebo

    Participants administer once daily, PO, 26 weeks

06

What researchers measure

Primary outcomes

  1. Safety: Number of Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)

    Time frame: From Baseline until 4 weeks after the end of treatment

Secondary outcomes

  1. Change from Baseline in Clinical Dementia Rating Scale Sum of Boxes (CDR-SB) after 26-week treatment

    Time frame: Baseline and Week 26

  2. Change from Baseline in Mini Mental State Exam (MMSE) after 26-week treatment

    Time frame: Baseline and Week 26

  3. Change from Baseline in Alzheimer's Disease Assessment Scale-Cognitive 13 (ADAS-Cog 13) after 26-week treatment

    Time frame: Baseline and Week 26

  4. Change from Baseline in Clinician's Interview Based Impression of Change-Plus Caregiver Input (CIBIC-Plus) after 26-week treatment

    Time frame: Baseline and Week 26

  5. Change from Baseline in Alzheimer's Disease Composite Score (ADCOMS) after 26-week treatment

    Time frame: Baseline and Week 26

Other outcomes

  1. Pharmacodynamics: Change in concentrations of plasma AD-related biomarkers

    To assess the effect of BEY2153 on amyloid (Aβ40, Aβ42) and tau (p-tau217, p-tau181, t-tau) related biomarkers in AD patients

    Time frame: Baseline, Week 6 and Week 26

  2. Brain imaging: Change in brain accumulation of amyloid protein

    Amyloid PET will be conducted following administration of BEY2153 to evaluate the change in brain accumulation of amyloid protein (centiloid)

    Time frame: Baseline and Week 26

  3. Brain imaging: Change in brain atrophy

    vMRI will be conducted following administration of BEY2153 to evaluate the change in brain atrophy (volume)

    Time frame: Baseline and Week 26

07

Study locations

3 sites
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jul 2025; primary completion for Jul 2028, 36 months later.

Of 131 industry-sponsored phase 2 interventional studies under Alzheimer Disease, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 39. This study's planned 36 months is above that.

Counting every sponsor, half of 259 studies reached it within 37 months; a quarter within 21 and three quarters within 58.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 10, 2025
First posted
Mar 20, 2025
StartEst.
Jul 2025
Primary completionEst.
Jul 2028
CompletionEst.
Aug 2028
Last update
Mar 20, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 20, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06885567
Lead sponsor
BeyondBio Inc.
Responsible party
Sponsor
First posted
Mar 20, 2025
Start date
Jul 2025 (estimated)
Primary completion
Jul 2028 (estimated)
Completion
Aug 2028 (estimated)
Last update
Mar 20, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Mar 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion